RxDoctor Payments Data

Elliot Borgen, MD

Interventional Cardiology · Brooklyn, NYNPI 1528017852

Payments from drug & device makers

$4,586in general payments, 2019–2025

Across 135 payments — averaging $33.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$728
  • Medtronic$514
  • Novartis$378
  • AstraZeneca$230
  • Edwards Lifesciences$229
  • plus $1K from 15 others

What the payments were for

  • Travel & lodging$1,27628%
  • Food & beverage$3,21070%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,586 in reported general payments places this provider in the 30th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$170,994
Medicare patients
1,212
Services billed
2,400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban266$310,039
EntrestoSacubitril/Valsartan206$243,810
FarxigaDapagliflozin Propanediol111$118,073
XareltoRivaroxaban45$47,313
JardianceEmpagliflozin32$27,111
BrilintaTicagrelor37$25,311
Praluent PenAlirocumab12$16,074
MultaqDronedarone Hcl12$14,272
OzempicSemaglutide13$12,097
DapagliflozinDapagliflozin Propanediol14$11,757
Metoprolol Succinate414$6,779
Valsartan139$4,015
Amlodipine-ValsartanAmlodipine Besylate/Valsartan76$3,756
Ezetimibe101$3,707
Atorvastatin Calcium274$3,329

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$138$310,039266 claims
NovartisEntresto$378$243,810206 claims
AstraZenecaFarxiga, Brilinta$230$143,385148 claims
Johnson & JohnsonXarelto$183$47,31345 claims
Boehringer IngelheimJardiance$28$27,11132 claims
Sanofi-aventis U.S. LLCMultaq$187$14,27212 claims
Novo NordiskOzempic$29$12,09713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →